Literature DB >> 364626

A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis.

J Powell-Tuck, R L Bown, J E Lennard-Jones.   

Abstract

Forty mg has been shown to be the optimal daily dosage of prednisone for outpatients requiring oral steroids for active proctocolitis. Although daily doses of oral steroids are commonly divided, a single dose each morning causes less adrenal suppression and is more convenient to take. A randomized controlled trial has been performed on patients with proctocolitis, in which 23 received 40 mg prednisolone each morning as one dose, and 22 received 10 mg four times a day, over two weeks. Physicians unaware of the dosage schedule scored the disease activity and assessed the steroid side-effects when the patient entered the trial, at day 7 and at day 14. Of those taking the divided dose the disease improved in 17 and failed to improve in five. No side-effects were observed in ten patients. Of those receiving a once daily regimen, 17 improved and six did not. Nine patients had no side-effects. Further assessment showed no difference between the two groups either in response rate or side-effects produced. When oral steroids are indicated for active proctocolitis, 40 mg prednisolone, as a single dose each morning can be recommended.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 364626     DOI: 10.3109/00365527809182199

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  80 in total

Review 1.  Ulcerative colitis.

Authors:  S Ghosh; A Shand; A Ferguson
Journal:  BMJ       Date:  2000-04-22

2.  Gut lavage IgG and interleukin 1 receptor antagonist:interleukin 1 beta ratio as markers of intestinal inflammation in children with inflammatory bowel disease.

Authors:  R Troncone; N Caputo; A Campanozzi; M Cucciardi; V Esposito; R Russo; B De Vizia; L Greco; S Cucchiara
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

Review 3.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 4.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

5.  Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease.

Authors:  Y R Mahida; A Gallagher; L Kurlak; C J Hawkey
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

Review 6.  Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.

Authors:  Britt Christensen; David T Rubin
Journal:  Curr Gastroenterol Rep       Date:  2016-01

Review 7.  Drug management of ulcerative colitis.

Authors:  M A Kamm; A Senapati
Journal:  BMJ       Date:  1992-07-04

8.  Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis.

Authors:  Francesco Azzolini; Cristiano Pagnini; Lorenzo Camellini; Antonella Scarcelli; Alberto Merighi; Anna Maria Primerano; Angela Bertani; Aldo Antonioli; Federico Manenti; Gian Piero Rigo
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

9.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 10.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.